Rapid Itch Relief Seen with Nemolizumab - Top-Institutions - MDSpire

Rapid Itch Relief Seen with Nemolizumab

Researchers examined early itch and sleep outcomes with interleukin-31 pathway inhibition in atopic dermatitis and prurigo nodularis in phase 3 trial analyses.

  • By

  • Kathryn Wighton

  • January 8, 2026

  • 3 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #4

    Massachusetts General Hospital (MGH) Dermatology
    Massachusetts General Hospital (MGH) Dermatology

    Boston, MA

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunology

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

Original Source(s)

Rapid Itch Relief Seen with Nemolizumab

  • by Kathryn Wighton

  • January 8, 2026

Related Content

Medical Oddities: Brain Health, Sunny-Side Up

Breakfast, bacteria, and brain wiring—small things show big implications this week.

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics